Estimating Microvascular Invasion in Patients with Resectable Multinodular Hepatocellular Carcinoma by Using Preoperative Contrast-Enhanced MRI: Establishment and Validation of a Risk Score

J Hepatocell Carcinoma. 2023 Jul 20:10:1143-1156. doi: 10.2147/JHC.S410237. eCollection 2023.

Abstract

Objective: To determine the preoperative clinicoradiological factors to predict microvascular invasion (MVI) in patients with resectable multinodular hepatocellular carcinoma (mHCC), and further to establish and validate a stratified risk scoring system.

Methods: Two hundred and seventy-three patients with pathologically confirmed mHCC (≥2 lesions) without major vascular invasion and biliary tract tumor thrombosis, who underwent preoperative contrast-enhanced MRI and hepatectomy, were consecutively enrolled (training/validation cohort=193/80). Preoperative clinicoradiological variables were collected and analyzed. The multivariable logistic regression was performed to determine the independent predictors of MVI and create a risk score system. The C-index, calibration curve and decision curve were used to evaluate the performance of the risk score. A risk score-based prognostic stratification system was performed in mHCC patients. The risk score system was further verified in the validation cohort.

Results: AFP > 400 ng/mL, presence of satellite nodule, mosaic architecture and increased total tumor diameter were independent predictors of MVI while fat in mass was an independent protective factor of MVI. The risk score yielded satisfactory C-index values (training/validation cohort: 0.777/0.758) and fitted well in calibration curves. Decision curve analysis further confirmed its clinical utility. Based on the risk score, mHCC patients were stratified into high-/low-MVI-risk subgroups with significantly different recurrence-free survival (both P < 0.001).

Conclusion: The presented risk score incorporating clinicoradiological parameters could stratify mHCC patients into high-risk and low-risk subgroups and predict prognosis in patients with resectable mHCC.

Keywords: hepatocellular carcinoma; magnetic resonance imaging; prognosis; statistical model.

Grants and funding

This study has received funding by Shanghai Municipal Health Commission (grant number 202240152), the National Natural Science Foundation of China (grant number 82171897), Shanghai Municipal Key Clinical Specialty (grant number shslczdzk03202), Clinical Research Plan of SHDC (grant number SHDC2020CR1029B), China National Key R&D Program (grant number 2022YFC2401605), Scientific Research Development Plan of SHDC and UNITED IMAGING (grant number SKLY2022CRT201), “Science and Technology Innovation Action Plan” Star Cultivation (Sailing Program) (grant number 22YF1443600) and Youth Foundation of Shanghai Municipal Health Commission (20204Y0346).